Aurinia Pharmaceuticals Inc (AUPH) Fair Value & Analysis
Healthcare · US · Market cap $2.0B · ISIN CA05156V1022
What is Aurinia Pharmaceuticals Inc really worth?
Aurinia Pharmaceuticals Inc
AUPH · US
A strong business, trading 35% below our fair value of $24.69.
Strengths
Risks
Fair value as of: Aug 31, 2026
From 24 valuation models · updated 5 days ago
Share price +8.0% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The rarer combination: high quality (82/100) AND below fair value. That earns a closer look rather than a quick verdict.
- The model range is unusually wide ($14.31 to $43.03). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 31, 2026.
How to read this chart
60‑month range $4.11 – $33.08 · fair‑value band $14.31 – $43.03 · the $16.12 price screens below the $24.69 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 31, 2026.
Analysis
Aurinia Pharmaceuticals Inc (AUPH) currently trades at $16.12, while our model-based Fair Value estimate is $24.69, implying the stock looks roughly 34.7% undervalued today. The Quality Score stands at 82/100 (high quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of $103.76 per share, and 15 of the 24 models we run sit above the $16.12 price. Bear case: the Asset-Based group reads lowest at $3.03, and 9 of the 24 models stay below the price. Evidence for this calculation is medium.
Over the trailing twelve months, Aurinia Pharmaceuticals Inc generated revenue of $298M at a net margin of 100.0%. Revenue grew 24.4% year over year. It earns a return on equity of 65.0%. The balance sheet holds a net cash position of $5.4M. Fundamentals as of Aug 31, 2026
Our scenario range runs from $14.31 (bear case) to $43.03 (bull case); at $16.12, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. Analysts expect earnings well below the last reported figure (earnings in transition, for example expiring patents or contracts); a fair value that looks fair on trailing earnings may then be too optimistic. The share trades about 5% below its 52-week high and 121% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −59% fair-value upside, at 53%, AUPH screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly $1.46 per share, which is 5.9 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 24 models by family
Widest divergence: Growth Earnings ($103.76) versus Asset-Based ($3.03). Highest evidence: EPV (74).
Notify me when AUPH reaches fair value
Put AUPH on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 31, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 78 · Market factors (momentum, volatility) 53
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Full company description
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Aurinia Pharmaceuticals Inc reported revenue of $283M in FY2025 versus $45.6M in FY2021, a compound +57.8%/yr. Reported net income was $287M in FY2025.
Watch AUPH: get an alert when its fair value changes →
Recent news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)?
- Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
- How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Extended Voclosporin Exclusivity And Share Buyback
- Aurinia settles Lupkynis patent litigation with Teva
Peer Group
Biotechnology · 622 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 66/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 31, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $547.55 | $278.78 | −49% |
| Regeneron Pharmaceuticals, Inc REGN | $807.71 | $594.40 | −26% |
| argenx SE ARGX | €877.60 | €292.84 | −67% |
| Samsung Biologics Co 207940 | 1,518,000 KRW | 1,055,793 KRW | −30% |
| CSL Limited CSL | A$174.50 | A$141.68 | −19% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | −77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | −60% |
| Celltrion, Inc 068270 | 190,700 KRW | 74,519 KRW | −61% |
| BeOne Medicines AG ONC | $362.51 | $111.35 | −69% |
| BioNTech SE BNTX | $111.40 | $45.66 | −59% |
Compare Aurinia Pharmaceuticals Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Aurinia Pharmaceuticals Inc (AUPH) overvalued or undervalued?
What is the fair value of AUPH?
What is the quality score of AUPH?
What is the revenue of Aurinia Pharmaceuticals Inc (AUPH)?
What is the net profit margin of AUPH?
Watch Aurinia Pharmaceuticals Inc in the live analysis
One click puts Aurinia Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.